Linking Treatment Outcomes and Patient Perception in CIDP- version 1

  • Research type

    Research Study

  • Full title

    Understanding the relationship between the treatment outcomes of Chronic Inflammatory Demyelinating Polyneuropathy and the patients’ perception of improvement.

  • IRAS ID

    337069

  • Contact name

    Kabir Khan Nazeer

  • Contact email

    220428790@aston.ac.uk

  • Sponsor organisation

    Aston University

  • Clinicaltrials.gov Identifier

    NA, NA

  • Duration of Study in the UK

    1 years, 1 months, 1 days

  • Research summary


    Chronic inflammatory demyelinating polyneuropathy( CIDP ) is a rare condition where the immune system attacks the lining of the peripheral nerves. The condition causes ongoing nerve damage leading to weakness and reduced sensation in the limbs. It can affect any age group, and its exact cause is unknown.

    Diagnosing CIDP is based on clinical evaluation of patient symptoms, examination of strength and reflexes and nerve tests. Treatment typically involves suppressing immune overactivity with steroids, immunoglobulins and plasma exchange. Since there are no reliable biomarkers, the response to the treatment is evaluated by the clinician using scales that assess improvement in physical function (functional outcomes) and the patient performance of daily activities (Patient-reported outcome measures). However, some items in these scales are irrelevant to patients' life and might fail to capture improvement-or-not in activities they consider relevant or how they feel about the effect of treatment.

    Our study aims to investigate the agreement between functional outcomes measured with clinical scales and the perception of change after treatment in patients with CIDP using the Patient's Global Impression of Change (PGIC) which is a 7-point scale that scores what the patient thinks about the efficacy of treatment.

    We also want to understand how sociodemographic; well-being, comorbidities and disease characteristics influence the current disease state and the patients’ subjective perception of change in their disease symptoms after treatment.

    This study participants with CIDP will be recruited from the Queen Elizabeth Hospital Birmingham and the study will be conducted at the Aston University.

  • REC name

    London - Queen Square Research Ethics Committee

  • REC reference

    25/LO/0786

  • Date of REC Opinion

    1 Dec 2025

  • REC opinion

    Further Information Favourable Opinion